Tempus AI, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tempus reported Q2 2026 revenue of $382.5M (up 22% YoY), with oncology diagnostics volume +31% and Data Licensing revenue +36%. On July 20, 2026, the company announced a definitive agreement to acquire Personalis for $16.25/share (~$1.5B enterprise value), integrating its ultrasensitive MRD technology. Tempus also completed a $460M offering of 0% convertible notes due 2032 and raised 2026 revenue guidance to $1.595–$1.605B (~25% growth).
Why this rating
Personalis acquisition (~13.6% of market cap) is material; strong Q2 growth and elevated FY guidance support strategy. But execution risk and debt increase warrant caution.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.